APA (7th ed.) Citation

Leavitt, A. D., Mahlangu, J., Raheja, P., Symington, E., Quon, D. V., Giermasz, A., . . . Ozelo, M. C. (2024). Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Research and practice in thrombosis and haemostasis, 8(8), 102615. https://doi.org/10.1016/j.rpth.2024.102615

Chicago Style (17th ed.) Citation

Leavitt, Andrew D., et al. "Efficacy, Safety, and Quality of Life 4 Years After Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 GENEr8-1 Trial." Research and Practice in Thrombosis and Haemostasis 8, no. 8 (2024): 102615. https://doi.org/10.1016/j.rpth.2024.102615.

MLA (9th ed.) Citation

Leavitt, Andrew D., et al. "Efficacy, Safety, and Quality of Life 4 Years After Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 GENEr8-1 Trial." Research and Practice in Thrombosis and Haemostasis, vol. 8, no. 8, 2024, p. 102615, https://doi.org/10.1016/j.rpth.2024.102615.